Chemotherapy-induced peripheral neuropathy may be under-recognised in cancer survivors and require better management strategies

With an estimated 32 million cancer survivors worldwide,1 it is increasingly important to understand the potential long-lasting impacts of successful cancer treatments. Neurological side effects of chemotherapy, including chemotherapy-induced peripheral neuropathy (CIPN), often produce persistent symptoms affecting sensation and balance in cancer survivors. Despite successful cancer treatment and long-term survival prospects, survivors may be left with long-term functional disability and reduced quality of life.2 In the current issue of JNNP, Shah and colleagues3 examine the incidence of CIPN in a population-based cohort—highlighting the need for greater insights into CIPN risk factors, management and treatment options.

While many studies have focused on the incidence of CIPN in a cancer-specific or chemotherapy-specific population, Shah and colleagues3 used a population-based approach, …